September 11, 2020
MSD said on September 10 that it has filed its anti-PD-1 antibody Keytruda (pembrolizumab) for an additional indication of microsatellite instability-high (MSI-H) unresectable advanced/recurrent colorectal cancer. The submission rides on the back of data from the KEYNOTE-177 study of the...read more